Chris Ryan

Dr Richardson on Optimal Treatment Strategies for 1q–Amplified Multiple Myeloma

May 30th 2025

Paul G. Richardson, MD, discusses the activity of quadruplet regimens containing daratumumab or isatuximab in patients with 1q-amplified multiple myeloma.

Dr Cortese on Future Directions for the Multiomic Investigation of Venetoclax in CLL

May 30th 2025

Matthew Cortese, MD, MPH, discusses the next steps for the multiomic evaluation of venetoclax activity in chronic lymphocytic leukemia.

Novel Treatment Approaches Under Investigation in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on novel approaches being investigated in ROS1-positive non–small cell lung cancer.

Another FDA-Approved Option? The Potential Role for Taletrectinib in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, on how FDA approval of taletrectinib would affect ROS1-positive non–small cell lung cancer management.

Pooled Data for Taletrectinib in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss data for taletrectinib in ROS1-positive non–small cell lung cancer.

Addressing CNS Involvement in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss CNS involvement in ROS1-positive non–small cell lung cancer.

Selecting a TKI in ROS1+ NSCLC Management

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss TKI selection in ROS1-positive non–small cell lung cancer.

Treatment Sequencing Decisions in ROS1+ NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss treatment sequencing in ROS1-positive non–small cell lung cancer.

The Prevalence of ROS1 Fusions in Advanced NSCLC

May 30th 2025

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss the prevalence of ROS1 fusions in non–small cell lung cancer.

Ivonescimab Plus Chemo Meets PFS End Point in EGFR+ NSCLC After an EGFR TKI

May 30th 2025

Ivonescimab plus chemotherapy improved PFS vs chemotherapy alone in second- and later-line EGFR-mutated non–small cell lung cancer.

Zanidatamab Wins Approval in China for Previously Treated, HER2+ Biliary Tract Cancer

May 30th 2025

China’s NMPA approved zanidatamab for previously treated, unresectable or metastatic, HER2-positive biliary tract cancer.

OncLive Polls Show Top Votes for Anticipated Gynecologic Cancer Abstracts at ASCO 2025

May 30th 2025

Experts from the gynecologic oncology space vote on their most anticipated abstracts on OncLive’s social media.

Encorafenib/Cetuximab Plus Chemo Boosts PFS in BRAF V600E+ mCRC

May 30th 2025

Encorafenib plus cetuximab and mFOLFOX6 improved progression-free survival in BRAF V600E–mutated metastatic colorectal cancer.

Dr Mosquera Orgueira on the Development of a Machine Learning–Based Prognostic Model for Risk Stratification in Myelofibrosis

May 29th 2025

Dr Maroto-Martin on the Mechanism of MZB1-Targeted CAR T-Cell Therapy in Myeloma and Waldenström Macroglobulinemia

May 29th 2025

Elena Maroto-Martin, PhD, discusses the mechanism of action and therapeutic rationale for an MZB1-targeted CAR T-cell therapy in of multiple myeloma and Waldenström macroglobulinemia.

BLA Is Withdrawn for Patritumab Deruxtecan in EGFR-Mutated NSCLC

May 29th 2025

The BLA seeking the approval of patritumab deruxtecan in EGFR-mutated non–small cell lung cancer has been voluntarily withdrawn.

ORIC-944 Plus AR Inhibition Yields PSA Responses in mCRPC

May 29th 2025

The addition of ORIC-944 to an AR pathway inhibitor generated PSA responses in metastatic castration-resistant prostate cancer.

FDA Grants Priority Review to Sevabertinib for HER2-Mutant NSCLC

May 28th 2025

The FDA granted priority review to sevabertinib for pretreated, advanced non–small cell lung cancer harboring HER2 mutations.

Dr Ali on the Need to Refine Predictive Strategies for Endocrine Sensitivity in HER2-Low Breast Cancer

May 28th 2025

Azka Ali, MD, discusses the need to refine predictive strategies for endocrine sensitivity in HER2-low metastatic breast cancer.

Awareness Efforts Aim to Improve Early Recognition and Multidisciplinary Care for Brain Tumors

May 28th 2025

Ryan Merrell, MD, underscores the need for early glioma detection, advances in IDH-targeted therapy, and emerging immunotherapy in glioblastoma care.